CN110169961B

CN110169961B - Exercise rehabilitation compound essential oil

Info

Publication number: CN110169961B
Application number: CN201910506759.XA
Authority: CN
Inventors: 赵华祥
Original assignee: Poli Fragrant Medicine Technology Shanghai Co ltd
Current assignee: Poli Fragrant Medicine Technology Shanghai Co ltd
Priority date: 2019-06-12
Filing date: 2019-06-12
Publication date: 2022-04-08
Anticipated expiration: 2039-06-12
Also published as: CN110169961A

Abstract

The invention relates to a compound essential oil for sports rehabilitation. The compound essential oil for sports rehabilitation comprises the following components: limonene, eucalyptol, alpha-pinene, menthol, terpinyl acetate, linalool, menthone, 4-terpineol, sabinene, 3-thujene, beta-pinene, methyl eugenol, myrcene, p-cymene, beta-thujene, menthyl acetate, neryl acetate, alpha-curcumene, alpha-thujene, isomenthone, gamma-terpinene, carvacrol. The essential oil can repair fracture, sprain, blood stasis, arthralgia, lactic acid accumulation, and myalgia caused by exercise.

Description

Exercise rehabilitation compound essential oil

Technical Field

The invention relates to conditioning essential oil, and in particular relates to exercise rehabilitation compound essential oil.

Background

Healthy China is a strategic target of our country, four elements of health are pleasant mood, proper exercise, sufficient sleep and reasonable diet, exercise injury caused by incorrect exercise is an increase of extra cost of preventive medicine, including the phenomenon of early retirement caused by continuous exercise due to long-term injury which is not completely cured by athletes, the mainstream treatment modes of injury caused by exercise injury in modern medicine are medication, operation and physical treatment, and a human body needs to promote wound healing, remove blood stasis and relieve inflammation and pain in some physical natural modes. The natural essential oil is frequently used in western first-class clubs, so that blood stasis and lactic acid accumulation caused by exercise can be effectively relieved, and the exercise level is improved. The invention develops the sports rehabilitation essential oil based on the mechanisms of activating blood, removing blood stasis, relieving pain and eliminating inflammation of natural essential oil.

Disclosure of Invention

The invention aims to solve the technical problem of providing the sports rehabilitation compound essential oil for repairing fracture, sprain, blood stasis and arthralgia caused by sports.

In order to solve the technical problem, the technical scheme provided by the invention is as follows:

the compound essential oil for sports rehabilitation is characterized by comprising the following components:

limonene

Eucalyptol

Alpha-pinene

Menthol

Terpinyl acetate

Linalool

Menthones

4-terpineol

Sabinene derivatives

3-arborvitae

Beta-pinene

Methyl eugenol

Myrcene

P-cymene

Beta-sirlinenes

Menthyl acetate

Neryl acetate

Alpha-curcumene

Alpha-sirlinenes

Isomenthone

Gamma terpinenes

Terpinene

Carvacrol.

Further, the compound essential oil for the rehabilitation of sports is provided, and the weight ratio of each component is as follows:

further, the compound essential oil for the rehabilitation of sports is provided, and the compound essential oil comprises the following components in percentage by weight:

limonene (Limonene), capable of preventing the development of diabetic bone disease: limonene treatment can significantly enhance collagen synthesis, alkaline phosphatase activity, osteocalcin synthesis and mineralization of osteoblasts. The limonene-pretreated mouse osteoblast anterior cell line MC3T3-E1 cell can prevent cell death and apoptosis induced by Methylglyoxal (MG) and can reduce Endoplasmic Reticulum (ER) stress caused by MG. In addition, limonene treatment can significantly reduce magnesium-induced autophagy activity and reactive oxygen species release.

Eucalyptol (Eucalyptol) having the following effects: anti-inflammatory and analgesic: reduce edema and mechanical pain, reduce levels of inflammatory cytokines (IL-1, TNF-and IL-6); anti-inflammatory, analgesic, possibly a clinically relevant adjunct to the treatment of oral facial pain, which is probably eudesmol by acting as a TRPV 1 channel antagonist; anti-inflammatory effects in acute lung inflammation are exerted by decreasing matrix metalloproteinase-9 (MMP-9) expression and the extracellular signal-regulated kinase-dependent NF-B pathway. ② antibiosis: is an effective inhibitor of the salmonella typhimurium target protein L-asparaginase, and can be used as a safe substitute for chemical compounds for treating infections and combating multidrug-resistant bacteria; as an efflux pump inhibitor, the compound restores the inhibiting effect of the existing antibiotic (ciprofloxacin) on multiple drug-resistant bacteria (acinetobacter baumannii and pseudomonas aeruginosa); the preparation can obviously reduce the number of viable bacteria and candida albicans in the vagina, reduce the activity of myeloperoxidase of mouse vaginal tissue, inhibit the expression of proinflammatory cytokines (IL-1 beta, IL-6 and TNF-alpha), COX-2 and iNOS, inhibit the activation of NF-kB, increase the expression of anti-inflammatory cytokine IL-10, and inhibit the expression of proinflammatory cytokines in peritoneal macrophages stimulated by lipopolysaccharide and the activation of NF-kB.

alpha-Pinene (alpha-Pinene) having anti-inflammatory efficacy: alpha-pinene (alpha-pinene) has anti-inflammatory effect by inhibiting mitogen-activated protein kinases (MAPKs) and nuclear factor-kappa B (NF-k); the alpha-pinene has anti-inflammatory activity by inhibiting MAPK and NF-kB pathways of macrophages in the abdominal cavity of a mouse, and is a potential anti-inflammatory drug for treating various inflammatory diseases; intraperitoneal injection of α -pinene can reduce the ratio of Pancreatic Weight (PW) to Body Weight (BW) and the levels of serum amylase and lipase. Alpha-pinene treatment also reduces tissue damage and myeloperoxidase activity in the pancreas and lungs. In addition, alpha-pinene pretreatment reduces the production of pancreatic Tumor Necrosis Factor (TNF) -alpha, Interleukin (IL) -1 beta and IL-6 during acute pancreatitis induced by rana peptides. In vitro, α -pinene inhibits phycocyanin-induced in vitro pancreatic acinar cell death and cytokine production. These findings indicate that alpha-pinene has anti-inflammatory effects in the course of acute pancreatitis induced by rana japonica peptide

Menthol (Menthol), with the following efficacy: firstly, analgesia: the results of the study indicate that menthol may produce a central analgesic effect on inflammatory pain by blocking voltage-gated Na + and Ca2+ channels. Menthol is effective in reducing painful behavior caused by chemical irritation (capsaicin, acrolein, acetic acid), noxious heat, and inflammation (complete Freund's adjuvant). TRPM8 is the primary mediator of menthol-induced acute and inflammatory pain analgesia. Neuromuscular regulation: surface electromyography of the vastus lateralis, vastus medialis, and rectus femoris muscles were recorded using a miniature counter electrode while stimulating on the skin with a 5% menthol gel. As a result: in adults and the elderly, the rms electromyography of the vastus lateralis and vastus medialis was significantly elevated under menthol stimulation, but there was no significant difference between the two groups. The Mean Power Frequency (MPF) of the vastus lateralis muscle was significantly reduced after menthol stimulation in the elderly, but menthol was not significantly altered in adults. And (4) conclusion: neuromuscular modulation was observed with menthol gels at low loads. These findings may lead to a new method of muscle training to safely obtain fast muscles for the elderly.

Linalool (Linalool), having the following efficacy: the preparation method is characterized by comprising the following steps: anti-inflammatory-improvement of lung tissue: linalool reduces the expression of proinflammatory cytokines and inflammatory cell signaling proteins in vitro, endotoxemia mice treated with linalool in vivo have fewer alveolar leukocytes and cytokines, and improves lung histology, suggesting that linalool may contribute to the abrogation of the proinflammatory response of macrophages, particularly to endotoxin. Linalool attenuates LPS-induced tumor necrosis- α and interleukin-6 production both in vitro and in vivo. In addition, linalool blocks phosphorylation of I κ B α protein, p38, c-Jun terminal kinase, and extracellular signal-regulated kinase in LPS-stimulated RAW 264.7 cells. In vivo studies found that linalool reduced lung histological changes in mouse models. The results indicate that linalool inhibits inflammation both in vitro and in vivo, and may be a potential therapeutic candidate for the treatment of inflammatory diseases. Linalool inhibits cigarette smoke-induced lung inflammation by inhibiting NF- κ B activation. Anti-inflammatory-hepatoprotective: linalool reduces inflammatory reaction through Nrf 2 activation and NF-kB inhibition, and has a protective effect on liver injury induced by LPS/GalN. Protecting the heart: linalool up-regulates VEGF-B mRNA and protein levels, promotes activation of protein kinase B (Akt) and inhibition of glycogen synthase kinase-3 (GSK 3 β), and may be a complementary mechanism for cardioprotection. ③ local anesthesia: the in vivo psychopharmacological evaluation of linalool indicates that the compound has dose-dependent sedative effects on the central nervous system, including hypnotic, anticonvulsant, and hypothermic effects. These neurochemical effects may be associated with the local anesthetic activity of linalool. Linalool can reduce the evoked acetylcholine release, an effect that can be attributed to some interaction with presynaptic function. In addition, local anesthesia is shown for inhibition of the kinetics of mini-endplate current decay, both for voltage-induced and receptor-activated channels. Fourthly, analgesia: linalool reduces mechanical hypersensitivity and plantar edema in mice induced by Complete Freund's Adjuvant (CFA), and also reduces mechanical hypersensitivity induced by Partial Sciatic Nerve Ligation (PSNL), indicating that (-) -linalool may have potential significance in developing new clinically relevant drugs for treating persistent pain. The analgesic effect of (-) -linalool is mainly attributed to the stimulation of the cholinergic, opiate and dopaminergic systems, the local anaesthetic effect and the blocking of the N-methyl-D-aspartate (NMDA) receptor. (-) -linalool has certain inhibitory effect on hyperalgesia caused by carrageenan, L-glutamic acid and prostaglandin E-2, and suggests that the compound may have certain therapeutic effect on pain during neuron sensitization. (-) -linalool is the naturally occurring enantiomer of essential oils. The reduction of NO production/release is at least partly a molecular mechanism of the analgesic effect of (-) -linalool, probably via a mechanism involved in the cholinergic and glutamatergic systems. Fifth, antibiosis: linalool has antifungal effect on Candida albicans ATCC 14053, and the minimum inhibitory concentration is 8 mm. Linalool at sub-MIC concentrations also inhibited the formation of reproductive tubes and biofilms of this strain. Linalool has certain interference effect on the form conversion and biofilm formation of candida albicans. Linalool is an antifungal drug with the potential of resisting trichophyton rubrum, and is an important drug for skin diseases.

Menthone (Menthone) has cooling, pain relieving, itching relieving and anti-inflammatory effects: menthone is widely used as a cooling agent, an anti-irritant to relieve pain, and to treat pruritis. Menthone can inhibit Lipopolysaccharide (LPS) -induced proinflammatory cytokines, interleukin-1 beta (IL-1 beta) and tumor necrosis factor-alpha (TNF-alpha) and nuclear factor kappa KB (NF-kappa B) activity induced by LPS and other inflammatory agents, including 12-O-tetradecanoylphosphonate-13, hydrogen peroxide, okadaic acid and ceramide. Furthermore, our data also demonstrate that NF-. kappa.B migration into the nucleus, activated by LPS, is inhibited by menthone, and that both I-. kappa.B and the β -transduction repetitive inclusion protein (. beta. -TrCP) are involved in this inhibition.

4-terpineol (Terphin-4-ol) had the following efficacy: the method comprises the following steps: can reduce the content of ergosterol in fungus strain, and has antifungal activity against fungi of two species, Pseudomonas powelliae and nematode capsulata. Can induce apoptosis of human leukemia Molt-4 cell by endogenous and exogenous ways, inhibit proinflammatory mediator generated by active human monocyte, resist convulsion, inhibit oral candida, inhibit and kill methicillin-resistant staphylococcus aureus and coagulase-negative staphylococcus, have no toxicity to human fibroblast, and resist mouse AE17 interstitial tumor and B16 melanoma. ② anti-inflammatory: can inhibit the production of inflammatory mediators in human macrophages stimulated by Lipopolysaccharide (LPS), by interfering with the NF-kB, p38 or ERK MAPK pathway.

SABINENE (SABINENE) has the following effects: the method comprises the following steps: has activity against Staphylococcus aureus, enterococcus faecalis, Escherichia coli and Klebsiella pneumoniae. Sabinene showed antibacterial activity against the gram positive and gram negative bacteria tested, i.e. staphylococcus aureus, escherichia coli and its multi-drug resistant bacteria, methicillin-resistant staphylococcus aureus and escherichia coli producing extended spectrum beta-lactamase. ② oxidation resistance and anti-inflammation: sabinene significantly inhibits NO production without affecting cell viability and shows very potent NO scavenging potential, and can be explored as a natural source of new antioxidants and anti-inflammatory agents.

The invention also provides application of the motor rehabilitation compound essential oil in preparing motor rehabilitation products.

The preparation method of the essential oil provided by the invention can be obtained by obtaining the essential oil from the market and directly and uniformly mixing the essential oil.

Furthermore, natural essential oils can be obtained from aromatic plants by essential oil extraction methods such as steam distillation and supercritical carbon dioxide extraction, for example, natural essential oils can be obtained by extracting from various plants such as permanent flower, thyme, eucalyptus oil, mint, marjoram, frankincense, myrrh, pine, lavender, clove, cinnamon and the like, then obtaining the corresponding chemical components such as limonene, eucalyptol, alpha-pinene, menthol, terpinyl acetate, linalool, menthone, 4-terpineol, sabinene, 3-thujene, beta-pinene, methyl eugenol, myrcene, p-cymene and the like by fractionation technology, and then mixing the components according to a certain proportion.

The application method of the essential oil provided by the invention can be used for directly applying the essential oil to a pain part and massaging and absorbing the essential oil.

In the sports rehabilitation product, the dosage of the sports rehabilitation compound essential oil is 1ML per time and 3 times per day. The product can be made into aerosol, spray, incense, and nasal inhalant.

The invention has the beneficial effects that: the essential oil provided by the invention is extracted from plants containing natural active ingredients, has scientific formula and mixture ratio, is safe without toxic and side effects, does not add any artificially synthesized components, and can repair fracture, sprain, blood stasis, arthralgia, lactic acid accumulation and muscle pain caused by movement.

Drawings

FIG. 1 is SPME-GC/MS analysis spectrum of the motor rehabilitation compound essential oil of the invention.

Detailed Description

The invention will be further illustrated with reference to the following specific examples. It should be understood that these examples are for illustrative purposes only and are not intended to limit the scope of the present invention. The experimental procedures, in which specific conditions are not noted in the following examples, are generally carried out according to conventional conditions or according to conditions recommended by the manufacturers. All percentages, ratios, proportions, or parts are by weight unless otherwise specified.

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. In addition, any methods and materials similar or equivalent to those described herein can be used in the methods of the present invention. The preferred embodiments and materials described herein are intended to be exemplary only.

Example 1

The preparation of the depression-relieving sleep-aiding compound essential oil comprises the following steps: the essential oil is prepared by mixing the following essential oils in parts by weight:

example 2 ingredient confirmation of the Compound essential oil for exercise rehabilitation according to the present invention

The motor rehabilitation compound essential oil of the invention is sent to be tested (Shanghai Yangxiang Biotech Co., Ltd.), the number of the sent to be tested is 190125-1, SPME-GC/MS detection analysis is carried out, and the result is shown in figure 1.

Example 3 population test of the Compound essential oil for exercise rehabilitation of the present invention

Experiment, the effect of the compound essential oil for sports rehabilitation on the permeability of the capillary vessel of the mouse caused by acetic acid

18-22g of male Kunming mice were selected 108 and randomly divided into 9 groups of 12 mice each. Group 1 was a positive control group, which was gavaged with 2.5mg/kg indomethacin tablets prior to the test; the group 2 is a blank control group 1, and cotton balls soaked with 1.0g of physiological saline are put into the squirrel cage in the group during the test; group 3 was blank control group 2, which was swabbed with 1.0g of physiological saline at the time of the test; group 4, the high dose inhalation group of example 1, which placed cotton balls having 2.0g of essential oil absorbed into the squirrel cage at the time of the test; group 5, the dose inhalation group of example 1, which placed cotton balls having 1.0g of essential oil absorbed into the squirrel cage at the time of the test; group 6, the low dose inhalation group of example 1, which placed cotton balls having 0.5g of essential oil absorbed into the squirrel cage at the time of the test; group 7 was the high dose wipe group of example 1, which was swabbed with 2.0g of essential oil on mice at the time of the trial; group 8, the dose-swabbing group of example 1, swabbed 1.0g of essential oil into mice at the time of the trial; group 9 was the low dose wipe group of example 1, which was swabbed with 0.5g of essential oil on mice at the time of the trial. The cotton balls were changed 2 times daily in groups 2 and 4-6.

1h after the last administration, 0.1mL/10g of Evans blue staining solution with 0.5% concentration is injected into tail vein, 0.1mL/10g of acetic acid solution with 0.6% concentration is injected into abdominal cavity, the abdominal cavity is killed after 20min, 5mL of physiological saline is used for washing the abdominal cavity, washing liquid is centrifuged for 5min at 1500r/min, supernatant is taken at 590nm, and the absorbance is measured. The results are shown in Table 1.

Table 1 influence of the compound essential oil for exercise rehabilitation of the present invention on the permeability of capillary vessels of mice induced by acetic acid

Group of	Dosage form	Absorbance of the solution
			Positive control group	2.5mg/kg	0.586±0.285^**
Blank control group 1	0	1.516±0.154
			Blank control 2 group	0	1.454±0.268
High dose inhalation group	2.0g	0.762±0.387^**
			Medium dose inhalation group	1.0g	1.231±0.296
Low dose inhalation group	0.5g	1.398±0.421
			High dose wipe set	2.0g	0.595±0.166^**
Medium dose wiping group	1.0g	0.968±0.233^*
			Low dose wipe set	0.5g	1.106±0.356^*

^*p<0.05 ^**p<0.01

Experiment II the effect of the compound essential oil for sports rehabilitation on the swelling of rat feet caused by carrageenan

108 wistar rats weighing 180 + -10 g were selected and randomly divided into 9 groups of 12 rats each. Group 1 was a positive control group, which was gavaged with 2.5mg/kg indomethacin tablets prior to the test; the group 2 is a blank control group 1, and cotton balls soaked with 1.0g of physiological saline are put into the squirrel cage in the group during the test; group 3 was blank control group 2, which was swabbed with 1.0g of physiological saline at the time of the test; group 4, the high dose inhalation group of example 1, which placed cotton balls having 2.0g of essential oil absorbed into the squirrel cage at the time of the test; group 5, the dose inhalation group of example 1, which placed cotton balls having 1.0g of essential oil absorbed into the squirrel cage at the time of the test; group 6, the low dose inhalation group of example 1, which placed cotton balls having 0.5g of essential oil absorbed into the squirrel cage at the time of the test; group 7 was the high dose wipe group of example 1, which was swabbed with 2.0g of essential oil on mice at the time of the trial; group 8, the dose-swabbing group of example 1, swabbed 1.0g of essential oil into mice at the time of the trial; group 9 was the low dose wipe group of example 1, which was swabbed with 0.5g of essential oil on mice at the time of the trial. The cotton balls were changed 2 times daily in groups 2 and 4-6. For 5 consecutive days.

Before the last administration, the volume of toes of each group of rats was measured, and 30min after the last administration, the right hind toes of each group of rats were injected with 0.1ml of a 1% carrageenan solution, and the toe solvents were measured at 1h, 2h and 4h, respectively, to calculate the swelling and swelling degree. Swelling degree of foot is the volume of the postinflammatory toe-the volume of the anteinflammatory toe. The results are shown in Table 2.

Table 2 influence of the compound essential oil for exercise rehabilitation of the present invention on swelling of rat feet caused by carrageenan

^*p<0.05 ^**p<0.01

The high, medium and low dose inhalation groups were not significantly different from the blank control group, and are not listed here.

Experiment three

The test participated people had strain, kick and ankle swelling caused by exercise, and 65 people with different ages, different sexes, such as cervical spondylosis, lumbar muscle strain and the like caused by long-term sitting posture. The using method comprises the following steps: the essential oil is applied to pain part, and is applied and absorbed at a dosage of 1ml each time and 3 times per day (1 ml/time, 3 times/day).

And (3) test results: the average recovery period of 40 sprain and strain patients is 18 days; the 20 cervical spondylosis patients recover in 10 days on average; pain was significantly relieved in 5 arthritic patients for 15 days.

The foregoing is only a preferred embodiment of the invention and is not intended to limit the scope of the invention, which is defined broadly in the claims appended hereto, and any entity or method that is obvious from the disclosure of the claims is intended to be encompassed by the claims, if it is identical or equivalent to that defined in the claims.

Claims

1. The compound essential oil for sports rehabilitation is characterized by comprising the following components in parts by weight:

2. the compound essential oil for motor rehabilitation according to claim 1, which is characterized by comprising the following components in percentage:

3. use of the compound essential oil for motor rehabilitation according to claim 1 or 2 in the preparation of a motor rehabilitation product.

4. The use of claim 3, wherein the amount of the compound essential oil for exercise rehabilitation in the exercise rehabilitation product is 0.5-2 ml.

5. The use of claim 4, wherein the amount of the compound essential oil for exercise rehabilitation in the exercise rehabilitation product is 0.5 ml.

6. The use of claim 4, wherein the motor rehabilitation product is a paint-on.

7. Use according to any one of claims 3 to 5, wherein the product is in a dosage form selected from: aerosols, sprays, fragrances or nasal inhalants.